Show simple item record

dc.contributor.authorBuchter, Valentin
dc.contributor.authorHess, Jeannine
dc.contributor.authorGasser, Gilles
dc.contributor.authorKeiser, Jennifer
dc.date.accessioned2018-11-07T07:02:39Z
dc.date.available2018-11-07T07:02:39Z
dc.date.issued2018-11-06
dc.identifier.citationParasites & Vectors. 2018 Nov 06;11(1):580
dc.identifier.issn1756-3305
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/284718
dc.description.abstractBACKGROUND: Schistosomiasis is one of the most harmful parasitic diseases worldwide, praziquantel being the only drug in widespread use to treat it. We recently demonstrated that ferrocenyl, ruthenocenyl and benzyl derivatives of oxamniquine (Fc-OXA, Rc-OXA and Bn-OXA) are promising antischistosomal drug candidates. METHODS: In this study we assessed the tegumental damage of these three derivatives of oxamniquine using scanning electron microscopy. Adult Schistosoma mansoni and S. haematobium were exposed to a concentration of 100 μM of each drug and incubated for 4-120 h, according to their onset of action and activity. RESULTS: While on S. mansoni the fastest acting compound was Fc-OXA, which revealed high activity after 4 h of incubation, on S. haematobium, Rc-OXA revealed the quickest onset, being lethal on all males within 24 h. In both species studied, the three derivatives showed the same patterns of tegumental damage consisting of blebs, sloughing and tegument rupturing all over the body. Additionally, on S. mansoni distinct patterns of tegumental damage were observed for each of the compounds: tissue ruptures in the gynaecophoric canal for Fc-OXA, loss of spines for Rc-OXA and oral sucker rupture for Bn-OXA. CONCLUSIONS: Our study confirmed that Fc-OXA, Rc-OXA and Bn-OXA are promising broad spectrum antischistosomal drug candidates. All derivatives show fast in vitro activity against S. mansoni and S. haematobium while validating the previous finding that the parent drug oxamniquine is less active in vitro under the conditions described. This work sets the base for further studies on the identification of a lead oxamniquine derivative, with the aim of identifying a molecule with the potential to become a new drug for human use.
dc.publisherSpringer Science and Business Media LLC
dc.titleAssessment of tegumental damage to Schistosoma mansoni and S. haematobium after in vitro exposure to ferrocenyl, ruthenocenyl and benzyl derivatives of oxamniquine using scanning electron microscopy.
dc.typeJournal Article
dc.date.updated2018-11-07T07:02:37Z
dc.language.rfc3066en
dc.rights.holderThe Author(s).
prism.publicationNameParasit Vectors
dc.identifier.doi10.17863/CAM.32090
dcterms.dateAccepted2018-10-02
rioxxterms.versionofrecord10.1186/s13071-018-3132-x
dc.contributor.orcidHess, Jeannine [0000-0001-5916-0728]
dc.contributor.orcidGasser, Gilles [0000-0002-4244-5097]
dc.contributor.orcidKeiser, Jennifer [0000-0003-0290-3521]
dc.identifier.eissn1756-3305
cam.issuedOnline2018-11-06


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record